ACHL

ACHL


Appropriate Antibiotic Selection in Multidrug-Resistant Pneumonia with Gram-Negative Bacteria: Identifying Pathogens and Related Antimicrobial Stewardship

Filmed at a prominent infectious disease meeting in October 2018, experts James Lewis, PharmD and James McKinnell, MD offer a lively discussion and clinical analysis of current optimal management of multidrug-resistant Gram-negative pseudomonas-based pneumonia infections in the context of a complex patient case. The purpose of this activity is to update physicians and pharmacists that may co...
ACHL

Breaking the Cycle of C. difficile: Focus on Community-acquired Infections and Recurrence

In this CME video-based interview, Dr. Sahil Khanna will review the changing epidemiology of community-acquired C. difficile and advances in its diagnosis and prevention. Dr. Khanna will also discuss approaches to the treatment of initial and recurrent episodes of C. difficile. A patient who experienced several episodes of recurrent C. difficile will provide her perspective.
ACHL

C. difficile Infection and Recurrence: Targeting the Drivers of Pathogenesis

In this CME eNewsletter, Dr. Paul Feuerstadt will discuss the body’s defenses against C. difficile infection, including the immune response and changes in the gut microbiome. He will also discuss the effect of available therapies on these processes during the treatment of initial and recurrent episodes of C. difficile. This is the final activity in a series of three educational activities on C...
ACHL

Clinical Case Challenges: Timely Diagnosis of Pulmonary Fibrosis

Pulmonary fibrosis includes a large, heterogeneous group of many different entities. Making a differential diagnosis is challenging, and patients report delays or frustrations when receiving a diagnosis. Yet, a prompt, accurate diagnosis is needed to guide treatment decisions. This case-based activity will take clinicians through the integration of clinical, radiologic, and pathologic data when ...
ACHL

Clinical Updates in Chronic Myeloid Leukemia: New Understandings in Disease Diagnosis, Monitoring and Personalized Therapeutic Regimens Utilizing Tyrosine Kinase Inhibitors

Advance your understanding on how to better diagnose, treat, and monitor CML. Expert faculty from MD Anderson recently gave a series of lectures across the country on the latest research and treatment regimen recommendations in CML. Highlighting key takeaways from this meeting series, faculty review the role of ABL tyrosine kinase inhibitor (TKI) agents in advancing treatment and delivering up-t...
ACHL

Clinical Updates in SSc-ILD and Application of Emerging Data: Diagnosis, Treatment, and Prognosis

In this 30-minute webinar, Cleveland Clinic pulmonologist Dr. Kristin B. Highland discusses the application of emerging data in the diagnosis, treatment, and prognosis of systemic sclerosis with interstitial lung disease (SSc-ILD). Strategies will be provided for clinicians to: • Enact timely, accurate SSc-ILD diagnoses • Optimize SSc-ILD treatment selection, considerate of individual pa...
ACHL

Evaluating Long-term Atherothrombotic Risks and Combination Antithrombotic Therapy in CAD Patients

Patients who experience a cardiovascular event and/or have peripheral artery disease require long-term antithrombotic prophylaxis to reduce the risk of recurrent cardiac events. Formulating complex regimens for secondary prevention of subsequent cardiovascular events and improved long-term cardiovascular outcomes poses a significant clinical challenge, and patients continue to experience events ...
Indiana University School of Medicine

Evaluating the Risk of Major Adverse Limb Events and Antithrombotic Therapy in PAD Patients

Patients who experience a cardiovascular event and/or have peripheral artery disease require long-term antithrombotic prophylaxis to reduce the risk of recurrent cardiac events. Formulating complex regimens for secondary prevention of subsequent cardiovascular events and improved long-term cardiovascular outcomes poses a significant clinical challenge, and patients continue to experience events ...
Indiana University School of Medicine

Expert Insights on the Use of PCSK9 Inhibitors in Interventional Cardiology

This roundtable discussion includes a panel of three faculty experts, who review clinical evidence related to the use of PCSK9 inhibitors in managing hyperlipidemia. Utilizing supporting clinical data and real-world experience, the faculty discuss how gaps in patient care can be improved via increased recognition of high-risk patients, application of clinical trial data, and selection of therapi...
ACHL

Expert Perspectives on New Guidelines and Approaches to Reduce Risk in Patients with C. difficile

In this CME video-based interview, Dr. David Binion will review the 2017 IDSA/SHEA guidelines for the treatment of initial and recurrent episodes of C. difficile. Dr. Binion will discuss data that informed the guidelines and the clinical implications of the guidelines. A patient will also provide her perspectives on experiencing several episodes of recurrent C. difficile. This is the first in a ...
ACHL

Faculty Rounds: Exploring the Advances in the Management of Invasive Fungal Infections

In this activity, expert Kathleen Mullane, DO, PharmD, responds to clinical challenges and barriers presented by faculty, James Lewis, PharmD, and George Thompson, MD. These rounds are offered to learners as 3 fungal infection modules: Mucormycosis, Candidiasis, Aspergillosis. The activity features a set of short, effective, and connected lessons that present clinical information surrounding the...
ACHL

Highlights from the 2018 C3 Symposium on the long-term effects of emerging cholesterol therapies in statin resistant patients and strategies for their management.

As presented at the 2018 C3 annual meeting, clinicians can learn about strategies to effectively apply new cholesterol therapies in diverse patient populations, clinical implications of the latest outcomes data from the FOURIER, ODYSSEY and SPIRE Trials, and access, cost, and non-adherence challenges of PCSK9 inhibitor therapy.
ACHL

JAK-STAT-GO: Personalized, Targeted Therapy Options for Your IBD Patients

How can clinicians know they have current information for improving patients’ IBD outcomes? Expert faculty from the Icahn School of Medicine at Mount Sinai, University of Chicago Medicine and Biological Sciences, and Montefiore Medical Center/Albert Einstein College of Medicine recently led a symposium at a major gastroenterology meeting exploring the latest in treat-to-target paradigms, the r...
ACHL

Novel Therapeutic Options in PAH: Addressing Complex Cases and Emerging Research

In this video-based interview, Dan Schuller, MD reviews emerging management and therapeutic models for PAH treatment. Dr. Schuller addresses adverse therapeutic events, strategies for complex PAH cases, and related clinical trial data for both current and emerging PAH therapies. He additionally discusses advanced-practice strategies related to PAH disease classification, risk stratification, and...
ACHL

Optimizing Antibiotic Therapy to Treat Gram-negative Pathogens and Improve Outcomes in HAP/VAP

George Karam, MD reviews a HAP/VAP patient case presented along with a faculty panel at MAD-ID 2019. Discussion topics include challenges with P. aeruginosa, ensuring effectiveness of antibiotics while reducing resistance, as well as new and emerging approaches to Gram-negative organisms. The purpose of this activity is to provide clinicians who care for patients with serious infections with...
ACHL

Optimizing the Management of Clostridium difficile Infection (CDI)

Recorded at a prominent infectious-disease conference in October 2018, Carlene Muto, MD and Sahil Khanna, MBBS discuss new clinical practice guidelines from IDSA/SHEA and clinical best practices for optimal treatment of C. difficile infection. A C. difficile patient and survivor of 8 infection recurrences (9 total infections) also presents her story for expert panel discussion/analysis and audie...
ACHL

Partnering with Patients to Navigate the Complexities of Idiopathic Pulmonary Fibrosis

Put your knowledge to the test with the IPF Formative Assessment! Challenge yourself with this self-paced interactive assessment designed to sharpen your knowledge and competency in the diagnosis and management of idiopathic pulmonary fibrosis. The Formative Assessment platform profiles individual learning needs related to the management of IPF and recommends personalized education to meet each ...
ACHL

Shared Decision Making and Improved Patient Participation in PAH Care: Strategies for Community and Specialist Practitioners

In this digital Q&A interview, expert faculty Dan Schuller, MD provides his perspective on collaborative strategies between provider and patient to increase PAH treatment adherence and improve PAH outcomes via shared clinical decision making. A current PAH patient will also share her experience with diagnosis and related patient insights on shared decision making.
ACHL

Targeted Nutrition Delivery in Critically Ill Patients: Focus on Protein Needs and Delivery

Filmed in conjunction with APSEN 2019 Nutrition Science and Practice Conference, this activity features an expert panel who discuss nutritional support for critically ill patients including a comparison of guidelines, the importance of tailoring therapy to optimize protein delivery, and the appropriate use of new and emerging high-protein/energy-restricted PN products in hospital settings. T...
ACHL

Targeting EGFR Mutation-positive NSCLC: Critical Advances in Care

New developments in the role of mutations in the epidermal growth factor receptor (EGFR) gene are transforming the understanding of how NSCLC progresses as a disease. This insight has enabled NSCLC to evolve from an untreatable disease to one where a number of novel therapeutic options are available, and individualized treatment regimens are now offered to optimize care. This digital flipbook...
ACHL

Treating Tardive Dyskinesia: Clinical Challenges and Patient Perspectives

This Clinical Commentary consists of an HD video roundtable discussion with two leading expert psychiatrists in the field, who participate in a panel discussion of tardive dyskinesia (TD) as a widespread and undertreated condition in psychiatric populations, as well as the importance of evidence-based differential diagnostics, newly approved therapeutics for treatment of the condition, and strat...
ACHL

RXinsider, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps. RXinsider, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map.